SAN DIEGO, July 31, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the market launch of its proprietary new generation monitoring ...

The San Diego-based pharmaceutical company Prometheus Laboratories has launched PROMETHEUS Anser VDZ, a monitoring test for inflammatory bowel disease patients using vedolizumab. 1. The PROMETHEUS ...

Saliva-based diagnostic detects genes related to the disease and calculates risk. Prometheus has selected DNA Genotek’s Oragene®•DNA product as the sample-collection kit for MyCeliacID™, a ...

WASHINGTON (AP) — The Supreme Court unanimously tossed out medical patent claims for Prometheus Laboratories on Tuesday for a test that could help doctors set drug doses for autoimmune diseases like ...

Respondr TNF is a proprietary test that uses objective evidence to predict an individual patient's likelihood of response to infliximab, adalimumab or their biosimilars prior to initiation of therapy.

Prometheus Laboratories announced the launch of its monitoring test, PROMETHEUS Anser IFX, which measures infliximab (Remicade; Janssen Biotech) and infliximab antibody levels in one sample to be used ...